BACKGROUND {#S5}
==========

In healthy, full-term neonates, the intestine is seeded by microbial inocula received from the birth canal, maternal skin, and milk, and the gut microbiome is dominated by Gram-positive Firmicutes such as *Staphylococcus*, *Propionibacterium*, *Bifidobacterium*, and *Lactobacillus* ([@R1]). Increasing pre-clinical and epidemiological information now acknowledges the positive influence of these bacteria on mucosal homeostasis, immunity, nutrient absorption, and energy regulation in the neonatal intestine ([@R2],[@R3]). In contrast, in preterm infants, the intestinal microbiome may develop very differently ([@R4]). In these infants, the hospital microflora may contribute more to the gut microbiome, whereas the maternal influence may be curtailed due to shortened labor or a Cesarean birth, limited physical contact with the mother, and periods of enteral fasting. There may be additional selection pressures from broad-spectrum antibiotics, indwelling tubes and catheters, intestinal dysmotility, and immaturity of barriers such as gastric acid, secretory IgA, and mucus ([@R1]). Not surprisingly, many preterm infants develop an enteric dysbiosis with a preponderance of Gram-negative bacteria of the class Gammaproteobacteria and its constituent families *Enterobacteriaceae*, *Vibrionaceae*, and *Pseudomonadaceae (*[@R5]--[@R8]). Emerging epidemiological data link such dysbiosis with adverse outcomes such as necrotizing enterocolitis, cholestasis, and developmental delay ([@R4],[@R6],[@R7],[@R9]), but the mechanism(s) by which Gammaproteobacteria present in the bowel lumen may evoke inflammatory responses are not well-understood. Intestinal epithelium and many resident immune cell lineages are normally tolerant of Gram-negative bacteria ([@R10]), and further study is needed to ascertain if dysbiosis secondary to a gammaproteobacterial bloom may induce mucosal inflammation when the relative abundance of Gammaproteobacteria exceeds a critical threshold, or is associated with an increase in specific pathobionts in this class of bacteria.

In this prospective observational study, we investigated the relationship between fecal Gammaproteobacteria and mucosal inflammation in premature infants. We used fecal calprotectin (FC), which is derived from neutrophils and inflammatory macrophages present in the mucosa, as the inflammatory marker ([@R11]). Preterm infants tend to have greater variability in FC expression than older children and adults, but several studies now show FC to be a useful marker of intestinal inflammation and necrotizing enterocolitis (NEC) when cut-off values between 200--300 μg/g of stool were used ([@R11]--[@R14]). We hypothesized that that FC increases in preterm infants as a function of the relative abundance of Gammaproteobacteria in stool. To test this hypothesis, we recorded demographic and clinical information from a cohort of very-low-birth weight (VLBW) infants, surveyed their fecal microbiome, and measured FC at serial time-points during the neonatal period.

METHODS: {#S6}
========

Demographic and clinical information: {#S7}
-------------------------------------

This study was performed at University of South Florida and the affiliated Tampa General Hospital (TGH) under appropriate oversight from the Institutional Review Boards. The neonatal intensive care unit (NICU) at TGH is an academic regional referral center with a single-patient room floor plan. All eligible VLBW infants were enrolled during the period May 2012 to December 2013; inclusion criteria included birth weight \<1500 g, availability of a stool sample in the first 2 weeks after birth, and parental informed consent. Infants with major congenital anomalies or lethal chromosomal disorders were excluded. Three stool samples were obtained from each infant at ≤2, 3^rd^, and the 4^th^ week after birth and stored at −80°C until the time of analysis. Biological samples were handled under uniform conditions per accepted guidelines (biospecimen reporting for improved study quality). ([@R15])

Fecal DNA amplification: {#S8}
------------------------

Total DNA was extracted from 100--250 mg of stool (MoBio PowerFecal DNA kit, Qiagen, Carlsbad, CA) and V4 region of bacterial 16S rRNA gene was amplified by polymerase chain reaction with modified 515F and 806R primers ([@R16]). Amplicons were sequenced according to Illumina MiSeq protocol (Illumina, San Diego, CA) to generate about 15,000 of 250 base-pair paired-end reads per sample.

Metagenomic analysis: {#S9}
---------------------

Demultiplexed DNA sequences were first uploaded to the CLC Biomedical Workbench 3.5.3 (Qiagen) and analyzed for bacterial classifications to genus level. Bacterial Operational Taxonomic Units (OTUs) were mapped to the Greengenes v13.8 reference database at 97% similarity, and their relative abundances (%) were computed. Diversity within samples (alpha diversity) were measured and represented by the number of OTUs, phylodiversity, Chao 1, Simpson, and Shannon indices. To improve taxonomic resolution, we next used the Divisive Amplicon De-noising Algorithm 2 (DADA2) to characterize bacterial OTUs to amplicon sequence variants (ASVs). This 2-step analysis provided information on OTUs to allow comparison with existing studies of the preterm microbiome ([@R5]--[@R7],[@R17]--[@R19]), and allowed validation of our results with the DADA2 pipeline that relies on a different, model-based approach to minimize amplicon errors.

Changes in the abundance of individual OTUs were investigated using Gneiss (balance tree) analysis ([@R20]). Due to the compositional nature of 16S rRNA gene sequence data, the relative (proportional) abundance of a taxon could be altered either due to a change in its own numbers or due to a shift in the relative abundance of other taxa. Balance tree analysis circumvents this problem by leveraging the correlation between co-occurring taxa to infer meaningful properties of sub-communities, rather than individual taxa.

Fecal Calprotectin (FC) measurements: {#S10}
-------------------------------------

We used a commercially-available enzyme immunoassay (PhiCal, Genova Diagnostics, Ashville, NC). The linear range of measurement for this assay is 25--2500 μg/g stool.

Statistical Analysis: {#S11}
---------------------

Clinical and demographic data were analyzed using SPSS 25 (IBM, Armonk, NY). Scalar variables were compared by Friedman's test for repeated measures or the Mann-Whitney *U* test, and categorical variables by Fisher's exact test. Linear mixed-effects models were used to identify determinants of FC and *Klebsiella* abundance. Small-for-gestational age (SGA), ethnicity, vaginal birth, antenatal steroids, magnesium sulfate, chorioamnionitis, gender, multiple births, postnatal age, enteral feedings (binary), respiratory distress syndrome, patency of ductus arteriosus, sepsis, red blood cell transfusions (binary), and *Klebsiella* abundance were defined as fixed effects as all possible levels of the variable were represented in the cohort. Maternal body-mass index (BMI), birth weight, gestation, postmenstrual age at stool collection, duration of ruptured membranes, and days of antibiotic treatment were defined as random effects. Mixed-effects procedures were performed using the maximum likelihood method and an autoregressive covariance matrix (with heterogeneous variances) as the dependent variables were anticipated to diverge with time. Best-fitting models were identified by −2 log likelihood, Akaike's information criterion, and Schwarz's Bayesian criterion. Important independent variables were shortlisted using bootstrap bagging, where a bootstrap dataset was constructed by not sampling a third of all subjects and replacing these by an equal number of duplicated samples. The bootstrap sample was analyzed by logistic regression with entry criterion of *p*\<0.2. To avoid model overfitting, multivariable analyses were limited to biologically plausible associations, to main effects for baseline measures, and time-dependent covariates for longitudinal measures.

We also performed linear regression to identify predictors of FC at different time-points of stool collection. Independent variables were tested with entry at *p*\<0.2 and acceptance at *p*\<0.05, first using a onestep forced entry and then 'stepwise' in the sequence of appearance during perinatal period. In addition to the variables listed above, duration of iron therapy was also tested. To identify highly-correlated variables, multicollinearity diagnostics (tolerance values \<0.2, variance inflation factors \>10) were reviewed. Independence of variables was confirmed by the Durbin-Watson statistic (acceptable range 1.5--2.5). Scatterplots of standardized residuals *vs*. standardized predicted values were evaluated for homoscedasticity and non-linearity. Normality of residuals was confirmed by evaluation of histograms. To determine *Klebsiella* abundance levels associated with elevated FC, we computed receiver-operating characteristics (ROCs) by plotting sensitivity *vs*. 1-specificity and identified 'cut-off' abundance values at the highest sum of sensitivity and specificity (Youden's *J* statistic). Statistical tests were two-tailed and considered significant at *p*\<0.05.

RESULTS {#S12}
=======

Demographic and clinical information: {#S13}
-------------------------------------

We enrolled 45 eligible VLBW infants admitted to our NICU between May 2012 and December 2013. The clinical characteristics of this cohort have been described in part, elsewhere ([@R21]). These infants were born at a gestation (mean ± standard deviation, SD) of 27.9±2.2 weeks, with birth weight 1126±208 g. Their clinical characteristics are summarized in [table 1](#T1){ref-type="table"} of our previous publication ([@R22]).

Fecal calprotectin: {#S14}
-------------------

Stool samples for the ≤2, 3^rd^, and 4^th^ week time-points were collected at postnatal age (mean ± SD) 9.9±3, 20.7±4.1, and 29.4±4.9 days; and post-menstrual age 29.8±2.3, 31.2±1.9, and 32.6±1.9 weeks, respectively. FC levels remained stable over time \[median (interquartile range/IQR): 161 (101--277), 187 (132--306), and 152 (102--311) μg/g stool in ≤2, 3^rd^ and 4^th^ week, respectively; Friedman's test; difference not significant (*N.S.*)\].

Fecal microbiome: {#S15}
-----------------

A total of 2,017,727 reads was obtained (mean ± SD 15,285±7,139 sequences per sample). The alpha-diversity metrics (number of OTUs, phylodiversity, and Shannon, Chao1, and Simpson indices) increased with postnatal age ([Figure 1](#F1){ref-type="fig"}). The relative abundance of Proteobacteria increased over time, comprising 46% (median; IQR = 0--90%) of all reads at ≤2 weeks, 83.5% (54.8--93.3%) in the 3^rd^, and 77% (57--88.3%) in the 4^th^ week (*p* \< 0.001). Gammaproteobacteria accounted for 42.5% (0--90%) of all reads in ≤2 weeks, 69.7% (29.9--86.9%) in the 3^rd^, and 75.5% (54.5--86%) in the 4^th^ week stool samples (*p*\<0.001). *Klebsiella* were the dominant gammaproteobacterial genus: median (IQR) 44% (2--98%), 85% (0--98%), and 78.5% (11.3--97.5%) in the \<2, 3^rd^, and 4^th^ week stool samples, respectively as summarized in supplemental table 3 of our previous publication.^22^ An ASV of *Klebsiella* accounted for nearly a third of all reads in weeks 3--4 \[median 0.18% (IQR 0--65%) at ≤2 weeks, 24.6% (0--80%) in the 3^rd^, and 26.2% (0.1--66.9%) in the 4^th^ week (*N.S.*)\].

Predictors of Fecal calprotectin: {#S16}
---------------------------------

In bivariate analyses, FC was positively correlated with birth weight (Spearman's *r* = 0.337, *p*\<0.001), particularly during the 3^rd^ (*r* = 0.417, *p* = 0.009) and 4^th^ weeks (*r* = 0.501, *p =* 0.005), but not with gestation or post-menstrual age. There was no correlation between FC and the relative abundance of Proteobacteria or its constituent Gammaproteobacteria (or the other major phyla, Firmicutes and Actinobacteria) in stool. Interestingly, FC was positively correlated with the genus *Klebsiella* (*r* = 0.207, *p* = 0.034) but not with other Gammaproteobacteria ([Table 1](#T1){ref-type="table"}). FC was also correlated with the *Klebsiella* ASV described above (*r* = 0.290, *p* = 0.003).

We used mixed-effects models to identify predictors of FC across the repeated measurements. The best-fitting, parsimonious model ([Table 2](#T2){ref-type="table"}) showed positive associations with vaginal birth (F = 83.29, *p* \< 0.001), Hispanic ethnicity (F = 7.89, *p* = 0.006), and *Klebsiella* abundance (F = 4.54, *p* = 0.035). The association with the dominant ASV of Klebsiella was even stronger (F = 7.37, *p* = 0.008). We also performed linear regression to identify determinants of FC at different time-points of stool collection. At ≤2 weeks, the best fitting model (*r*^2^ = 0.68, F = 35.76, *p*\<0.001) showed positive effects of maternal BMI (B = 6.08, *t* = 5.72, *p*\<0.001) and confirmed the association with vaginal birth (B = 157.62, *t* = 2.73, *p* = 0.01). During the 3^rd^ week (*r*^2^ = 0.8, F = 40.77, *p* \<0.001), FC was associated with birth weight (B = 0.3, *t* = 7.29, *p*\<0.001) and Hispanic ethnicity (B = 256.19, *t* = 3.52, *p* = 0.001), but days of iron supplementation had a negative impact (B = −20.8, *t* = −3.39, *p* = 0.002). In the 4^th^ week regression model (*r*^2^ = 0.61, F = 18.96, *p* \<0.001), the associations with birth weight (B = 0.2, *t* = 4.93, *p*\<0.001) and Hispanic ethnicity (B = 334.69, *t* = 2.08, *p* = 0.048) were still evident.

We also computed receiver-operating characteristics (ROCs) of *Klebsiella* abundance to identify a cut-off value that predicted high FC levels similar to those recorded in infants with mucosal inflammation (\>280 μg/g stool) ^12^. *Klebsiella* abundance ≥ 83% predicted FC\>280 μg/g with 72% sensitivity and 60% specificity (area under the curve, AUC = 0.646, *p* = 0.028; [Figure 2a](#F2){ref-type="fig"}). In the 3^rd^ week, *Klebsiella* abundance ≥ 76% predicted elevated FC with 89% sensitivity and 57% specificity (AUC = 0.722, *p* = 0.047; [Figure 2b](#F2){ref-type="fig"}).

Predictors of the relative abundance of *Klebsiella* in stool: {#S17}
--------------------------------------------------------------

Similar to the observed associations of FC, *Klebsiella* abundance was also related in mixed-effects models to vaginal birth (F = 5.68, *p* = 0.015) and Hispanic ethnicity (F = 124.33, *p*\<0.001). The dominant ASV of *Klebsiella* was also affected by the same clinical antecedents, vaginal birth (F = 13.46, *p*\<0.001) and Hispanic ethnicity (F = 57.81, *p*\<0.001).

Clustering of infants based on *Klebsiella* abundance at ≤ 2 weeks: {#S18}
-------------------------------------------------------------------

To investigate whether the variability (range 0--98%) in *Klebsiella* abundance we observed in the ≤2-week stool samples indicated the presence of more than one distinct subgroups of infants in our cohort, we used agglomerative hierarchical and K-means clustering procedures. These analyses revealed 2 subgroups with distinct cluster centers (13% *vs*. 94% in clusters 1 and 2, respectively; F = 370.83, p \<0.001; analysis of variance; [Figure 2](#F2){ref-type="fig"}). In cluster 1 (n = 23), the relative abundance of *Klebsiella* (and its dominant ASV) started at low levels and increased over time (Friedman test, *p* = 0.009 and 0.021 for *Klebsiella* and its dominant ASV, respectively). In contrast, *Klebsiella* dominated the intestinal microbiome in cluster 2 (n = 21). There was minimal loss of *Klebsiella* abundance over time (*p* = 0.018; [Table 3](#T3){ref-type="table"}) but the *Klebsiella* ASV remained stable. Gneiss (balance tree analysis) ^20^ confirmed that these cluster differences in *Klebsiella* abundance were significant and not merely due to decreased abundance of other taxa ([Figure 3](#F3){ref-type="fig"}). In support of these data, the accumulative ratios of major bacterial families *vs*. *Klebsiella* ([Figure 4](#F4){ref-type="fig"}) decreased over time in cluster 1, consistent with the acquisition of *Klebsiella*. Cluster 2 started with and maintained low ratios, indicating persistently high levels of *Klebsiella* compared to other taxa.

The two clusters were similar in birth weight and gestational age. Cluster 1 experienced a shorter duration of maternal ruptured membranes but had more days on antibiotics. There was no difference in major neonatal morbidities, days to full enteral feeds (150 mL/kg), days on positive pressure respiratory support, *Z-*scores for weight on postnatal day 28 and at 36 weeks' post-menstrual age (based on Fenton growth charts), and length of hospital stay. A summary of the clinical characteristics of the two clusters in [Table 4](#T4){ref-type="table"}.

In mixed-effects models, *Klebsiella* abundance in cluster 1 increased with postnatal age (F = 5.0, *p* = 0.028) and antenatal steroids (F = 5.8, *p* = 0.019), whereas antenatal magnesium sulfate (F = 8.5, *p* = 0.005) and chorioamniotitis (F=5.2, *p* = 0.026) had a negative effect. The association with antenatal steroids was also detectable in cluster 2 (F=5.3, *p* = 0.025). In cluster 1, *Klebsiella* ASV also increased with postnatal age (F = 5.8, *p* = 0.018), and decreased with antenatal magnesium sulfate (F = 8.1, *p* = 0.006) and chorioamnionitis (F = 4.6, *p* = 0.035). In cluster 2, Klebsiella ASV was associated with vaginal delivery (F = 6.6, *p* = 0.013).

Cluster 1 had lower FC levels overall than cluster 2 \[median (IQR) 148 (99--215) in cluster 1 *vs*. 226 (112--362) μg/g in cluster 2, respectively; *p* = 0.011). FC values were the highest in cluster 2 at ≤ 2 weeks \[median (IQR) 243 (121--331) μg/g in cluster 2 *vs*. 148 (83--199) in cluster 1; *p* = 0.04\]. Antenatal magnesium sulfate had a negative effect on FC in cluster 1 (F = 15.0, *p*\<0.001), but a positive effect was seen in cluster 2 (F=5.8, p=0.02). Antenatal steroids had a negative effect on FC in cluster 2 (F = 6.0, *p* = 0.018).

DISCUSSION {#S19}
==========

We present a detailed investigation of the relationship between fecal colonization with Gammaproteobacteria in VLBW infants and FC, a biomarker of gut mucosal inflammation. In our cohort, Gammaproteobacteria abundance did not affect FC expression. Instead, we found FC to be associated specifically with the presence of *Klebsiella*, and even more strongly, with a particular ASV within this genus. We observed two distinct paths to enteric colonization with *Klebsiella*: infants in cluster 1 began with very low abundance and gained modest levels of these bacteria over time, whereas the gut microbiome in cluster 2 was completely dominated by *Klebsiella*. High FC in cluster 2 infants indicated ongoing host-microbial interaction and a measureable innate immune response to these luminal bacteria. Importantly, *Klebsiella* abundance ≥ 83% predicted elevated FC levels similar to those seen during intestinal inflammation and NEC. To our knowledge, this is the first study to evaluate enteric dysbiosis in preterm infants in the context of the host inflammatory response.

The association of FC with fecal *Klebsiella* in our study raises several scientific questions. First, our findings call into question the practice of evaluating Gammaproteobacteria *en bloc* in the preterm microbiome. In recent years, several studies show that premature infants with a diagnosis of NEC had developed enteric dysbiosis with increased Gammaproteobacteria for several days to weeks antedating NEC onset ([@R5]--[@R8]). However, the lack of correlation between Gammaproteobacteria abundance and FC in our cohort suggests that Gammaproteobacteria may be too diverse a group to consistently exert a net inflammatory effect, and indicates a need for defining dysbiosis at higher levels of resolution. Second, we recorded highest FC levels in cluster 2 during the early neonatal period, when *Klebsiella* dominated in a setting of low alpha-diversity. These findings are important in efforts to develop a clinically-relevant definition for dysbiosis; further study is needed to clarify whether the relative abundance of a pathobiont is relevant in isolation, or if it needs to be interpreted in conjunction with the diversity indices. Third, further study is needed to determine whether the early appearance of *Klebsiella* in some premature infants was unique to our center or if it represents a universal phenomenon in Page 13 of 36 these patients. The inflammatory effects of *Klebsiella* in the intestine are plausible, considering the presence of potent virulence factors such as cell wall components and enterotoxins ([@R23],[@R24]). *Klebsiella* are recognized intestinal pathogens of preterm and term neonates, having been identified in diarrhea, ecchymotic colitis, bacteremia during NEC and short-bowel syndrome, and even in NEC outbreaks ([@R25]--[@R29]). The correlation between fecal *Klebsiella* and elevated FC has been previously noted in infantile colic ([@R30]). Early colonization with *Klebsiella* has been noted in other preterm cohorts ([@R6],[@R8]), but the possibility of finding distinct inflammation-driving pathobiont(s) at other centers cannot be excluded. In our own cohort, the correlation between FC and *Klebsiella* was relatively modest (*r* = 0.21), and when clustering was attempted based on FC, subgroup differences in *Klebsiella* did not reach significance. Finally, even though current evidence supports dysbiosis as an inflammatory stimulus, we need to acknowledge that a reciprocal effect, where pre-existing inflammation in the intestinal mucosa may promote a Gammaproteobacterial bloom, also warrants exploration.

Calprotectin is a 24 kDa dimer of the calcium-binding proteins calgranulin A/S100A8 and calgranulin B/S100A9, expressed in neutrophils and inflammatory monocytes ([@R11]--[@R14]). FC has found wide acceptance as a non-invasive marker of gut mucosal inflammation because it is strongly correlated with leukocyte infiltration in the mucosa, is stable in stool at room temperature for several days, and is easy to measure ([@R31]). Premature infants tend to have higher and more variable FC than adults, but higher cut-off values such as 280 μg/g stool have been correlated with intestinal inflammation and NEC ([@R11]--[@R14]). Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) can increase FC ^32^, but in our cohort, the FC levels in the 2 infants who received indomethacin for treatment of PDA were not higher than the rest.

Vaginal birth was an important determinant of the relative abundance of *Klebsiella* (and the dominant *Klebsiella*) in stool and of FC expression. These findings suggest that *Klebsiella* were likely acquired via vertical, mother-to-infant transmission. The near-total dominance of the gut microbiome in some infants (cluster 2) within the first 2 weeks after birth also lends credence to this possibility. However, the source of these bacteria is unclear. During pregnancy, the vaginal microbiome is dominated by Firmicutes ([@R33],[@R34]). In women with vaginal dysbiosis, pathobionts such as *Prevotella, Sneathia, Atopobium, Mycoplasma,* and *Gardnerella* can be identified, but *Klebsiella* are infrequent ([@R34]). Perinatal exposure to maternal enteric flora during vaginal birth and to the microbiome of human milk, which contain *Klebsiella* ([@R35],[@R36]), are two possible sources. Increased maternal BMI and diabetes have been previously associated with enrichment of *Enterobacteriaceae*, including *Klebsiella*, in both maternal and neonatal gut microbiome ([@R37]). Unfortunately, we are unable to investigate these findings further because we did not collect maternal samples in the present study.

We found higher *Klebsiella* abundance and FC in Hispanic infants. Although racial/ethnic differences in the enteric microbiome are possible ([@R38]), the type of feedings could have had a confounding influence: 8/9 (88.8%) Hispanic infants received only human milk *vs*. 17/36 (47.2%) infants of other ethnic groups (*p* = 0.03). The correlation between birth weight and FC likely reflects the maturational expansion of the mucosal leukocyte populations, and thus, the improving ability of the host to launch an innate immune response. Associations with antenatal steroids and magnesium sulfate may be more difficult to explain; steroids could influence the host-microbial cross-talk through altered leukocyte function and cytokine expression, and epigenetic changes in the mucosa ([@R39]). Perinatal exposure to magnesium sulfate can also alter gut motility and some immune responses ([@R40]), but the effects on fecal microbiome are unclear.

In conclusion, we show that FC expression in VLBW infants was specifically associated with the genus *Klebsiella* and a dominant ASV mapping to this genus, but not with the relative abundance of all Gammaproteobacteria in stool. These findings are important in the quest to develop a clinically-relevant definition of enteric dysbiosis in premature infants. Major strengths of our study are repeated measurements of the gut microbiome and FC, and the single-patient room floor-plan of our NICU, which now represents the layout in most of the newer NICUs in the United States. There are important limitations, such as the limited sample size and the single-center design. In our cohort, *Klebsiella* abundance affected FC but not the clinical outcome; we had only a single patient with NEC, which made it difficult to analyze the clinical effects of abnormal microbial colonization and mucosal inflammation. Further study is needed in a larger, multicenter Page 15 of 36 cohort to validate our findings, particularly to confirm the dichotomous development of the gut microbiome and the importance of *Klebsiella* as a leading pathobiont in preterm infants.
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![Longitudinal change in alpha-diversity indices.\
Boxplots (median and 95% confidence interval) summarize number of OTUs, Chao 1, Simpson, Shannon, and phylodiversity indices. (\*\*) and (\*\*\*) indicate p\<0.01 and p\<0.001 respectively in comparison to the ≤2 weeks samples.](nihms-1515822-f0001){#F1}

![Fecal *Klebsiella* predict FC expression:\
(**a**) Relative abundance of *Klebsiella* ≥ 83% in stool predicted high FC (\>280 μg/g of stool) with 72% sensitivity and 60% specificity (area under curve, AUC = 0.646); (**b**) During the 3^rd^ postnatal week, *Klebsiella* abundance ≥76% predicted high FC with 89% sensitivity and 57% specificity (AUC = 0.722).](nihms-1515822-f0002){#F2}

![Proportion plot based on balance tree calculation shows shifts in major genera between the two clusters.](nihms-1515822-f0003){#F3}

![Temporal change in bacterial abundances at family level relative to *Klebsiella* in the two clusters.\
*Top:* Boxplots summarize accumulative ratios of major bacterial families *vs*. *Klebsiella* (natural log-transformed, Ln) in the two patient clusters. *Bottom:* Bar diagrams summarize the distribution of major bacterial taxa at the family level in the numerator and the denominator.](nihms-1515822-f0004){#F4}

![Longitudinal change in fecal *Klebsiella* abundance.\
Scatter dot plots summarize fecal *Klebsiella* abundance over time. Open and solid circles indicate the two sub-groups of infants identified in our cohort by K-means clustering analysis of fecal *Klebsiella* abundance at ≤2 weeks. Cluster 1 (23 infants, open circles) started with low *Klebsiella* abundance and gained these bacteria over time (Friedman test, *p* = 0.009). Cluster 2 (21 infants, solid circles) showed high *Klebsiella* abundance with minor attrition in weeks 3 and 4 (*p* = 0.018).](nihms-1515822-f0005){#F5}

###### 

Bivariate correlation between FC and the relative abundance of major genera in the class Gammaproteobacteria

  Genus                r           p-value
  -------------------- ----------- -----------
  ***Klebsiella***     **0.207**   **0.034**
  *Haemophilus*        −0.023      0.820
  *Proteus*            −0.099      0.316
  *Acinetobacter*      0.089       0.365
  *Vibrio*             −0.142      0.148
  *Pseudomonas*        0.002       0.985
  *Enhydrobacter*      −0.040      0.685
  *Salmonella*         −0.084      0.392
  *Microbulbifer*      −0.103      0.297
  *Trabulsiella*       0.176       0.073
  *Arenimonas*         0.024       0.804
  *Photobacterium*     −0.041      0.680
  *Cardiobacterium*    −0.041      0.680
  *Serratia*           0.019       0.845
  *Stenotrophomonas*   −0.064      0.514
  *Morganella*         −0.007      0.946
  *Erwinia*            −0.057      0.566

###### 

Predictors of FC

  Parameter                          Estimate   Std. Error   df        t        p-value   95% Confidence Interval   
  ---------------------------------- ---------- ------------ --------- -------- --------- ------------------------- ---------
  Vaginal birth                      348.220    67.270       105.000   5.176    0.000     214.836                   481.604
  Non-Hispanic ethnicity             −127.186   51.705       105.000   −2.460   0.016     −229.707                  −24.664
  Relative abundance of Klebsiella   0.932      0.437        105.000   2.132    0.035     0.065                     1.799
  Female gender                      −61.289    36.944       105.000   −1.659   0.100     −134.542                  11.964

###### 

Klebsiella abundances in stool and FC over time, by cluster

               Cluster 1      Cluster 2                                                            
  ------------ -------------- --------------- ---------------- --------------- ------------------- ----------------
  ≤2 weeks     5 (0--30)      0 (0--0.1)      148 (83--199)    98 (94.5--99)   66.4 (0.7--94)      243 (121--331)
  3^rd^ week   19.5 (0--86)   0.1 (0--36.6)   162 (123--210)   98 (70--98.8)   80.7 (15.3--89.4)   227 (142--417)
  4^th^ week   21 (0--74.8)   0.3 (0--26.2)   134 (79--285)    96 (80--98)     59.6 (29.4--75.4)   163 (102--436)

###### 

Perinatal and Neonatal Clinical Characteristics of the Two Clusters

  Characteristic                                                    Cluster 1 N=23          Cluster 2 N=21          p values
  ----------------------------------------------------------------- ----------------------- ----------------------- -----------
  Gestational age (weeks, mean ± SD)                                28±2                    28±2                    0.281
                                                                                                                    
  Birth weight, grams, (mean, SD)                                   1099±220                1144±187                0.211
                                                                                                                    
  Male                                                              12 (52.2%)              8 (38.1%)               0.382
                                                                                                                    
  Hispanic ethnicity                                                4 (17.4%)               5 (23.8%)               0.716
                                                                                                                    
  Race                                                                                                              0.302
      Black                                                         12 (52.2%)              7 (33.3%)               
      White                                                         11 (47.8%)              13 (61.9%)              
                                                                                                                    
  Antenatal medications                                                                                             
      Steroids                                                      20 (87%)                19 (90.5%)              1.000
      Magnesium                                                     17 (73.9%)              17 (81%)                0.724
                                                                                                                    
  Vaginal birth                                                     4 (17.4%)               7 (33.3%)               0.303
                                                                                                                    
  Multiple birth                                                    6 (26.1%)               1 (4.8%)                0.097
                                                                                                                    
  **Ruptured membrane (hours, mean ± SD)**                          **17±64**               **65±173**              **0.038**
                                                                                                                    
  Chorioamnionitis                                                  15 (65.2%)              10 (47.6%)              0.521
                                                                                                                    
  Maternal hypertension                                             6 (26.1%)               7 (33.3%)               0.744
                                                                                                                    
  Small for gestational age                                         2 (8.7%)                1 (4.8%)                1.000
                                                                                                                    
  Respiratory distress syndrome                                     14 (60.9%)              26 (57.8%)              0.762
                                                                                                                    
  Oxygen on day 28                                                  6 (26.1%)               4 (19.0%)               0.724
                                                                                                                    
  Oxygen on day 36                                                  1 (8.7%)                1 (4.8%)                1.000
                                                                                                                    
  Significant patent ductus arteriosus                              2 (13.3%)               3 (14.3%)               0.658
                                                                                                                    
  Indomethacin                                                      0                       2 (9.5%)                0.222
                                                                                                                    
  Patent ductus arteriosus ligation                                 1 (2.2%)                0                       1.000
                                                                                                                    
  Retinopathy of prematurity                                        2 (8.7%)                4 (19%)                 0.403
                                                                                                                    
  Intraventricular hemorrhage                                       1 (4.3%)                4 (19%)                 0.176
                                                                                                                    
  Necrotizing enterocolitis                                         1 (4.3%)                0                       1.000
                                                                                                                    
  **Days on antibiotics, (mean, SD)**                               **5.3 (6.0)**           **3.7 (2.5)**           **0.045**
                                                                                                                    
  Positive blood culture                                            3 (13.0%)               2 (9.5%)                1.000
                                                                                                                    
  Packed red blood cell transfusion                                 7 (30.4%)               8 (38.1%)               0.752
                                                                                                                    
  Feeding type                                                                                                      0.936
      Maternal breast milk only                                     12 (52.2%)              12 (57.1%)              
      Formula only                                                  1 (4.3%)                1 (4.8%)                
      Mixed feeding types                                           10 (43.5%)              8 (38.1%)               
                                                                                                                    
  Days to full enteral feeds; median (range)                        11 (6--19)              11 (5--17)              0.623
                                                                                                                    
  Z-score for weight, postnatal day 28; median (range)              −0.89 (−3.72 to 1.14)   −0.52 (−2.56 to 1.71)   0.301
                                                                                                                    
  Z-score for weight, post-menstrual age 36 weeks; median (range)   −0.81 (−3.72 to 1.09)   −0.41 (−2.39 to 1.56)   0.459
                                                                                                                    
  Days on respiratory support                                       34 (0--92)              42 (0--68)              0.689
                                                                                                                    
  Discharge weight \<10^th^ percentile                              5 (21.7%)               6 (28.6%)               0.732
                                                                                                                    
  Length of stay (days, mean ± SD)                                  71±34                   64±21                   0.163
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